SCHEMBL25751625

SCHEMBL25751625

CCCCCCN1CCN(C)C1=NC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
GNAI3 P08754 2/20 0.36
GNAO1 P09471 2/20 0.36
GNAI1 P63096 2/20 0.36
HTT P42858 1/20 0.35
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
GBA1 P04062 1/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
SOAT1 P35610 2/20 0.32
EEF2K O00418 1/20 0.31
ABCB1 P08183 1/20 0.31
ALOX5 P09917 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
SOAT2 O75908 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751673 1.00 ALDH1A1 (0.37) ALDH1A1CYP1A2CYP2D6CYP2C19GNAI3
SCHEMBL25751683 1.00 ALDH1A1 (0.37) ALDH1A1CYP1A2CYP2D6CYP2C19GNAI3
SCHEMBL25751668 1.00 ALDH1A1 (0.37) ALDH1A1CYP1A2CYP2D6CYP2C19GNAI3
SCHEMBL25751672 0.93 MEN1 (0.36) MEN1KMT2A
SCHEMBL25751626 0.91 HTT (0.37) ALDH1A1CYP1A2CYP2D6CYP2C19GNAI3
SCHEMBL25767008 0.86
SCHEMBL25766999 0.86 FAAH (0.35) FAAHMGLLMEN1KMT2A
SCHEMBL25751615 0.86 L3MBTL1 (0.31)
SCHEMBL25751675 0.85
SCHEMBL25751618 0.84 MEN1 (0.39) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 ALDH1A1 1901/4885CYP1A2 4800/4885CYP2D6 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.